Repligen Corporation ($RGEN) Stock Forecast: Down 5.1% Today

What is Repligen Corporation?

Repligen Corporation is a global life sciences company specializing in bioprocessing technologies for biological drug manufacturing. The stock RGEN experienced a strong bearish movement in the market.

Why is Repligen Corporation going down?

RGEN stock is down 5.1% on Feb 12, 2026 18:17

• The announcement of Repligen Corporation reporting its fourth quarter and full year 2025 financial results may have raised concerns among investors, leading to a bearish sentiment.
• Azzad Asset Management Inc. ADV reducing its stake in RGEN by 60.7% in Q3 and the significant insider selling of shares in the last three months could have contributed to the negative market movement.
• Despite the endorsement from Baron Health Care Fund for Repligen's AI-driven bioprocessing platform, market sentiment may have been influenced by the cautionary advice for investors to consider various perspectives and risks, potentially impacting the stock price negatively.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Repligen Corporation (NASDAQ:RGEN) announced it will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will issue a press release before market open and host a conference call at 8:30 a.m. ET to discuss the results and business updates. Interested parties can access the call via a toll-free number or a webcast on the Investor Relations section of Repligen’s website.

https://www.globenewswire.com/news-release/2026/02/10/3235198/24603/en/Repligen-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Repligen Corporation announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and business updates. Repligen is a global life sciences company specializing in bioprocessing technologies for biological drug manufacturing.

https://www.manilatimes.net/2026/02/10/tmt-newswire/globenewswire/repligen-to-report-fourth-quarter-and-full-year-2025-financial-results/2275128

Azzad Asset Management Inc. ADV Has $1.09 Million Stock Holdings in Repligen Corporation $RGEN

Azzad Asset Management Inc. ADV reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 60.7% in Q3, now holding 8,183 shares valued at approximately $1.09 million. Despite this, other institutions increased their positions, and Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $179.62. Company insiders have sold shares totaling $7.72 million in the last three months, while institutional investors own nearly 97.64% of the stock.

https://www.marketbeat.com/instant-alerts/filing-azzad-asset-management-inc-adv-has-109-million-stock-holdings-in-repligen-corporation-rgen-2026-02-09/

How Investors May Respond To Repligen (RGEN) Winning Backing For Its AI-Driven Bioprocessing Platform

Baron Health Care Fund recently added Repligen (RGEN) to its portfolio, citing the company's bioprocessing technology, AI for real-time drug production monitoring, and potential for growth from pharmaceutical reshoring. This endorsement reinforces Repligen's investment narrative as a key supplier to biopharma, though market sentiment suggests it may not be a major short-term driver. Investors are advised to consider various perspectives and risks, including valuation and execution, despite the fund's backing.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/how-investors-may-respond-to-repligen-rgen-winning-backing-f

Trending Today

Repligen Corporation Price History

14.00.2026 - RGEN Stock was down 5.1%

• AI models analyzing RGEN suggest choppy conditions and conflicting sentiment across various time horizons.
• Institutional trading strategies suggest positions, momentum breakouts, and risk hedging with specified entry, target, and stop-loss levels.
• Multi-timeframe signal strengths, support, and resistance levels paint a challenging outlook for RGEN in the near-term, mid-term, and long-term.
• The bearish movement in RGEN's stock price is possibly due to the choppy market conditions and conflicting sentiment identified in the AI analysis, which have led to heightened selling pressure and a downward trend in the stock.

12.01.2026 - RGEN Stock was down 5.1%

• The announcement of Repligen Corporation reporting its fourth quarter and full year 2025 financial results may have raised concerns among investors, leading to a bearish sentiment.
• Azzad Asset Management Inc. ADV reducing its stake in RGEN by 60.7% in Q3 and the significant insider selling of shares in the last three months could have contributed to the negative market movement.
• Despite the endorsement from Baron Health Care Fund for Repligen's AI-driven bioprocessing platform, market sentiment may have been influenced by the cautionary advice for investors to consider various perspectives and risks, potentially impacting the stock price negatively.

05.01.2026 - RGEN Stock was down 6.1%

• The bearish movement in RGEN's stock price could be attributed to significant insider selling activity by company executives and institutional investors reducing their holdings.
• Despite the positive long-term outlook, the near and mid-term sentiment appears weak, leading to a downside target of 13.3%.
• The mixed institutional investor activity, with some increasing and others decreasing their positions, might have added to the selling pressure on RGEN's stock.
• The overall market sentiment towards RGEN remains cautiously optimistic, as indicated by the "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $179.62.

11.01.2026 - RGEN Stock was down 5.0%

• The anticipation of Repligen's fourth quarter and full year 2025 financial results might have caused uncertainty among investors, contributing to the bearish sentiment.
• Azzad Asset Management Inc. significantly reduced its stake in RGEN by 60.7%, possibly adding to the selling pressure and indicating reduced confidence from institutional investors.
• Baron Health Care Fund endorsed Repligen's AI-driven bioprocessing platform, but the market seemed more focused on recent insider selling and overall weak sentiment highlighted in technical analysis.
• An analysis reflecting a negative near and mid-term sentiment, suggesting a short setup and downside target, likely influenced traders to adopt a bearish position on RGEN. Monitoring price action is crucial for making tactical trading decisions.

21.10.2025 - RGEN Stock was up 5.5%

• The rise in RGEN's stock price is possibly a result of favorable investor sentiment towards the company's P/E ratio.
• Despite a slight decline in the previous month, the substantial increase in the stock price over the last year indicates promising long-term growth prospects, which may have attracted investors.
• The 0.65% increase in the current market session could also be influenced by general market positivity or specific industry trends benefiting biopharmaceutical firms like Repligen Inc.

22.07.2025 - RGEN Stock was up 5.4%

• The company revealed its involvement in three forthcoming investor conferences, hinting at possible growth prospects.
• Repligen's participation in these conferences could be perceived as a tactic to appeal to more investors and highlight its advancements in bioprocessing technology.
• Investors might interpret Repligen's proactive engagement with the investment community as a vote of confidence in its future potential, potentially attracting more buyers and boosting the stock price.

01.07.2025 - RGEN Stock was down 5.4%

• The stock's downward trend, which has persisted for over 1400 days, may have contributed to the bearish movement.
• While Repligen announced a strategic partnership with Novasign for bioprocessing digitalization, investors appeared more concerned about the long-term downtrend and associated risks.
• Market sentiment appears to have been influenced by technical analysis and Adhishthana principles, signaling ongoing weakness in the stock and leading to today's bearish movement.

17.06.2025 - RGEN Stock was up 5.0%

• Repligen Corporation announced the upcoming release of its second-quarter 2025 financial results, creating anticipation and positive sentiment among investors.
• The market might be reacting positively to the potential growth and performance indicators that could be revealed during the earnings call.
• Investors seem optimistic about Repligen's future prospects, leading to increased buying activity and driving the stock price higher.
• The strong bullish movement could be a reflection of confidence in Repligen's business strategies and financial health, as hinted by the upcoming financial report.

03.05.2025 - RGEN Stock was up 5.2%

• Upward trends are noticeable among options traders for Repligen (RGEN) stock, reflecting a positive market sentiment.
• The increased engagement in the options market implies expectations of favorable updates or progress related to Repligen's operations.
• This upsurge in positive activity may be linked to possible future collaborations, product introductions, or robust financial results, stimulating investor confidence and elevating the stock value.

23.09.2025 - RGEN Stock was up 5.4%

• Despite initial expectations of a decline in Q3 earnings, Repligen (RGEN) demonstrated a strong bullish performance, potentially signaling investor focus on other positive aspects.
• A comparison of Repligen (RGEN) with Alkermes (ALKS) may have contributed to increased investor interest, supporting the upward momentum in the market.
• Market sentiment towards Repligen (RGEN) potentially improved due to factors beyond earnings, such as anticipated growth opportunities or strategic advancements.

31.09.2025 - RGEN Stock was up 5.0%

• Despite strong Q3 earnings, with revenue growth surpassing expectations, Repligen (RGEN) witnessed a stock dip possibly due to revised EPS guidance.
• The current bullish market trend for RGEN implies a reevaluation of the initial response to the earnings, indicating a perceived undervaluation of the stock.
• Positive surprises in both earnings and revenues for Q3 may have boosted investor confidence, leading to increased buying activity and a rise in stock price.
• The uptrend in RGEN today may stem from investors revisiting the company's performance and recognizing it as a more appealing investment opportunity, despite the initial setback.

28.09.2025 - RGEN Stock was down 6.0%

• Despite exceeding earnings and revenue forecasts in Q3, Repligen (RGEN) faced a bearish trend, potentially triggering investor sell-off.
• Market sentiment towards Repligen may have been impacted by comparisons with Alkermes (ALKS) in terms of value, contributing to the stock's bearish performance.
• Investors seemed to have responded to the positive earnings results by selling shares to secure profits, resulting in a temporary dip in the stock's value.